ReviewCells2022
Acute Kidney Injury in Cancer Immunotherapy Recipients.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Risk stratification for immune checkpoint inhibitor rechallenge after acute kidney injury: towards a precision medicine framework.Frontiers in immunology · 2026Review
- Unraveling the mechanism of tetracycline-induced renal injury: an evaluation of drug safety based on network toxicology and molecular dynamics simulations.BMC pharmacology & toxicology · 2025Article
- Acute kidney injury: pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Intensive care unit outcomes and prognostic factors of esophageal cancer: A cross-sectional study in Chinese cancer-specialized hospitals.World journal of gastrointestinal oncology · 2025Article
- Adolescent Survivors of Childhood Cancer: Biopsychosocial Challenges and the Transition from Survival to Quality of Life.Children (Basel, Switzerland) · 2025Review
- Immune checkpoint inhibitors and renal toxicity.Heliyon · 2024Review
- From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma.Heliyon · 2024Review
- Review
- Recommendations for the effective use of T-cell-redirecting therapies: a Canadian consensus statement.Frontiers in oncology · 2024Review
- CAR T-cell therapy and the onco-nephrologist.Frontiers in nephrology · 2024Review
- Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies.OncoTargets and therapy · 2024Review
- Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.Frontiers in immunology · 2024Article
- CAR-T Cells and the Kidney: Insights from the WHO Safety Database.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Article
- More than Just Skin-Deep: A Review of Imaging's Role in Guiding CAR T-Cell Therapy for Advanced Melanoma.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy has now entered clinical practice and has reshaped the standard of care for many cancer patients. With these new strategies, specific toxicities have emerged, and renal side effects have been described. In this review, we will describe the causes of acute kidney injury in CAR T cell, immune checkpoint inhibitors and other cancer immuno-therapy recipients. CAR T cell therapy and bispecific T cell engaging antibodies can lead to acute kidney injury as a consequence of cytokine release syndrome, tumor lysis syndrome, sepsis or specific CAR T cell infiltration. Immune checkpoint blockade most often results in acute tubular interstitial nephritis, but glomerular diseases have also been described. Although the pathophysiology remains mostly elusive, we will describe the mechanisms of renal damage in these contexts, its prognosis and treatment. As the place of immunotherapy in the anti-cancer armamentarium is exponentially increasing, close collaboration between nephrologists and oncologists is of utmost importance to provide the best standard of care for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.